Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 161529.80%.
Cambio hacia las ganancias
El rendimiento de la empresa ha pasado a ser rentable. Sus ingresos netos anuales más recientes han sido de USD.
Valorada de forma justa
El PE más reciente de la empresa es -4.45, en un rango percentil medio de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 22.62M acciones, lo que supone una reducción del 59.03% con respecto al trimestre anterior.
En posesión de Steven Cohen
El inversor estrella Steven Cohen posee 106.10K acciones de este valor.